Ordering
Available Variants5 mg
CHA.98826-5mg
Price
€167.20
Available – Dispatch in 14 days
25 mg
CHA.98826-25mg
Price
€543.32
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.98826-5mg | €167.20 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.98826-25mg | €543.32 |
≥95% (HPLC), vascular targeting agent, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C27H40N8O7 · xC2HF3O2 |
|---|---|
| CAS Number | 188968-51-6 |
| Molecular Weight | 588.66 (free base basis) |
| UNSPSC Code | 12352106 |
| NACRES | NA.77 |
| Assay | ≥95% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
Technical Overview & Applications Use-case context
Cilengitide trifluoroacetic acid salt, with a CAS number of 199807-35-7, is a synthetic molecule that has garnered significant attention in the realm of cancer research. As an arginine-glycine-aspartate (RGD) peptide mimic, it exhibits high affinity for integrins, specifically targeting the alpha(v)beta(3) and alpha(v)beta(5) subtypes. This targeted approach allows cilengitide to effectively inhibit angiogenesis, the process by which new blood vessels form, thereby hindering tumor growth and metastasis. The trifluoroacetic acid salt form of cilengitide enhances its solubility and stability, rendering it more suitable for in vitro and in vivo studies. Researchers have explored its potential as a therapeutic agent in various cancer types, including glioblastoma, melanoma, and prostate cancer, with promising results underscoring its potential as a novel anti-cancer therapy. Further investigation is warranted to fully elucidate its clinical efficacy and safety profile.
